Paysign, INC 10-Q quarterly reports

Paysign, Inc. announced a substantial increase in revenues and net income for the second quarter of 2026, driven by strong performance in its plasma and pharma industry segments.

Paysign, Inc. announced a significant increase in total revenues and net income for the first quarter of 2026, driven by substantial growth in its pharma and plasma industries segments.

Paysign, Inc. reported a significant increase in Q3 2025 net income and revenue, driven by robust growth in its pharma patient affordability programs and expansion in plasma centers.

Paysign, Inc. reported a significant increase in net income and gross profit for Q2 2025, driven by robust growth in its pharma patient affordability programs.

Paysign's Q1 2025 net income surged to $2.59 million, driven by significant growth in the pharma industry, despite a decrease in plasma revenue.

Paysign's Q3 2024 results show significant revenue growth, particularly in the pharma and plasma sectors, leading to increased profitability.

Paysign Inc. announced a significant increase in revenue and net income for Q2 2024, fueled by growth in its plasma and pharmaceutical payment solutions.

Paysign's first quarter of 2024 saw a significant increase in revenue, driven by growth in both the pharmaceutical and plasma industries, resulting in a net income of $309,096.